Investor Relations

Company Overview

Humanigen, Inc. is a biopharmaceutical company pursuing cutting-edge science to develop its proprietary monoclonal antibodies for immunotherapy and oncology treatments. Derived from the company's Humaneered® platform, lenzilumab and ifabotuzumab are lead compounds in the portfolio of monoclonal antibodies with first-in-class mechanisms. Lenzilumab, which targets granulocyte-macrophage colony-stimulating factor (GM-CSF), is in development as a potential medicine to make chimeric antigen receptor T-cell (CAR-T) therapy safer and more effective, as well as a potential treatment for rare hematologic cancers such as chronic myelomonocytic leukemia (CMML) and juvenile myelomonocytic leukemia (JMML). Ifabotuzumab, which targets Ephrin type-A receptor 3 (EphA3), is under study as a potential treatment for glioblastoma multiforme (GBM) and other deadly cancers.

Latest Financial Results

FY 2017

Fiscal Year Ended Dec 31, 2017

Latest 10-K

For Fiscal Year 2017

Download 10-K

Stock Information

Symbol

OTCQB: HGEN

Price

Change

Volume

52 week Low/High

Day Low/High

Contact Information

Investor Relations

MZ Group
Mike Cole
T: 949-259-4988
mike.cole@mzgroup.us

Transfer Agent

Computershare Trust Company, N.A.
250 Royall Street
Canton, MA 02021
T: 800-662-7232
www.computershare.com